Literature DB >> 16717089

Peptide aptamer-mediated inhibition of target proteins by sequestration into aggresomes.

Evangelia Tomai1, Karin Butz, Claudia Lohrey, Fritz von Weizsäcker, Hanswalter Zentgraf, Felix Hoppe-Seyler.   

Abstract

Peptide aptamers (PAs) can be employed to block the intracellular function of target proteins. Little is known about the mechanism of PA-mediated protein inhibition. Here, we generated PAs that specifically bound to the duck hepatitis B virus (HBV) core protein. Among them, PA34 strongly blocked duck HBV replication by inhibiting viral capsid formation. We found that PA34 led to a dramatic intracellular redistribution of its target protein into perinuclear inclusion bodies, which exhibit the typical characteristics of aggresomes. As a result, the core protein is efficiently removed from the viral life cycle. Corresponding findings were obtained for bioactive PAs that bind to the HBV core protein or to the human papillomavirus-16 (HPV16) E6 protein, respectively. The observation that PAs induce the specific sequestration of bound proteins into aggresomes defines a novel mechanism as to how this new class of intracellular inhibitors blocks the function of their target proteins.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16717089     DOI: 10.1074/jbc.M604258200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Isolation of peptides blocking the function of anti-apoptotic Livin protein.

Authors:  Irena Crnković-Mertens; Julia Bulkescher; Christina Mensger; Felix Hoppe-Seyler; Karin Hoppe-Seyler
Journal:  Cell Mol Life Sci       Date:  2010-02-23       Impact factor: 9.261

2.  Inhibition of human cytomegalovirus replication via peptide aptamers directed against the nonconventional nuclear localization signal of the essential viral replication factor pUL84.

Authors:  Nina Kaiser; Peter Lischka; Nadine Wagenknecht; Thomas Stamminger
Journal:  J Virol       Date:  2009-09-09       Impact factor: 5.103

3.  Robust suppression of HIV replication by intracellularly expressed reverse transcriptase aptamers is independent of ribozyme processing.

Authors:  Margaret J Lange; Tarun K Sharma; Angela S Whatley; Linda A Landon; Michael A Tempesta; Marc C Johnson; Donald H Burke
Journal:  Mol Ther       Date:  2012-09-04       Impact factor: 11.454

Review 4.  The eleven-year switch of peptide aptamers.

Authors:  Pierre Colas
Journal:  J Biol       Date:  2008

Review 5.  Application of Aptamers in Virus Detection and Antiviral Therapy.

Authors:  Xinran Zou; Jing Wu; Jiaqi Gu; Li Shen; Lingxiang Mao
Journal:  Front Microbiol       Date:  2019-07-03       Impact factor: 5.640

Review 6.  Aptamers and their potential to selectively target aspects of EGF, Wnt/β-catenin and TGFβ-smad family signaling.

Authors:  Andrea Conidi; Veronique van den Berghe; Danny Huylebroeck
Journal:  Int J Mol Sci       Date:  2013-03-26       Impact factor: 5.923

7.  A RasGAP SH3 peptide aptamer inhibits RasGAP-Aurora interaction and induces caspase-independent tumor cell death.

Authors:  Perayot Pamonsinlapatham; Réda Hadj-Slimane; Françoise Raynaud; Marc Bickle; Claudine Corneloup; Audrey Barthelaix; Yves Lepelletier; Perrine Mercier; Matthieu Schapira; Jérôme Samson; Anne-Laure Mathieu; Nicolas Hugo; Olivier Moncorgé; Ivan Mikaelian; Sylvie Dufour; Christiane Garbay; Pierre Colas
Journal:  PLoS One       Date:  2008-08-06       Impact factor: 3.240

8.  Aggresomes do not represent a general cellular response to protein misfolding in mammalian cells.

Authors:  Simon Beaudoin; Kevin Goggin; Cyntia Bissonnette; Catherine Grenier; Xavier Roucou
Journal:  BMC Cell Biol       Date:  2008-10-20       Impact factor: 4.241

9.  Intracellular Analysis of the Interaction between the Human Papillomavirus Type 16 E6 Oncoprotein and Inhibitory Peptides.

Authors:  Christina Stutz; Eileen Reinz; Anja Honegger; Julia Bulkescher; Johannes Schweizer; Katia Zanier; Gilles Travé; Claudia Lohrey; Karin Hoppe-Seyler; Felix Hoppe-Seyler
Journal:  PLoS One       Date:  2015-07-07       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.